Skip to main content

Koken Licenses Alnylam's RNAi Patents for Research Uses

NEW YORK (GenomeWeb News) – Tokyo-based Koken has acquired the rights to use Alnylam Pharmaceuticals' RNAi-related patents under a non-exclusive, worldwide agreement, Alnylam said today.

Koken will use the patents from Alnylam's Kreutzer Limmer patent family, which covers aspects of the structure and functional properties of synthetic RNAi products, to manufacture and offer siRNA reagents to industry and academic researchers.

Alnylam VP of Business Development Jason Rhodes said in a statement that the company currently has more than 15 license agreements with global research products suppliers, including five in Asia.

"Access to the Kreutzer-Limmer patent estate enables us to augment our current RNAi products, thereby strengthening our position in the life sciences marketplace," Koken President Yuzo Tarumia said.

Financial terms of the agreement were not released.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.